A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

Recruiting

Phase 3

DMX-200 with ARBA Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

Sponsor:

Dimerix Bioscience Pty Ltd

Code:

NCT05183646

Conditions

FSGS

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

DMX-200

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-15. This information was provided to ClinicalTrials.gov by Dimerix Bioscience Pty Ltd on 2025-10-06.